The DNA-editing technology developer has raised $10m in addition to the $65m it pulled in from investors including Leaps by Bayer in November.
US-based gene editing technology developer Metagenomi added $10m to a series A round featuring chemical and pharmaceutical producer Bayer yesterday, increasing it to $75m. Investment manager RA Capital Management put up the extra cash and is co-leading the round with Bayer subsidiary Leaps by Bayer and venture capital fund Humboldt Fund. The November 2020 first…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.